Pepticom Ltd. is an innovative computational drug discovery company, privately co-owned by the Hebrew University of Jerusalem, seed investors and the scientifc team that developed Pepticom's unique technology. Pepticom is located in the Malcha Technological Gardens in Jerusalem, Israel.

Pepticom Ltd. developed exceptional computational software, which allows for the design of peptides that bind a target protein. This software is ab initio, requiring only the solved structure of the target protein to complete the design process. Peptides are designed in the three dimensional space, with three dimensional binding models and calculated binding energy provided as the primary output. The peptides undergo a complex design process, until eventually converging on to a diversified peptide library of optimal binding affinity.

Pepticom is an innovative computational drug discovery company founded on December 2011, based on novel ab-initio peptide design technology developed in the Hebrew University of Jerusalem (HUJI).

Pepticom is the commercial proprietor of elaborate research results in the fields of protein-protein and peptide-protein interactions performed in Professor Amiram Goldblum's Hebrew University laboratories.
As such, Pepticom's advantages are composed of both high end algorithms, such as the award winning Iterative Stochastic Eliminations (ISE, licensed to pepticom by the HUJI) algorithm as well as extensive "know how" in the field, gained in more than a decade of applying ISE to many problems. Furthermore, Pepticom developed and modified algorithms from financial portfolio optimizations and implemented them into the biomedical field.
Design process

Pepticom Ltd. developed unique computational software, which allows for the design of peptides that bind a target protein. This software is ab initio, requiring only the solved structure of the target protein to complete the design process. Peptides are designed in the three dimensional space, with three dimensional binding models and calculated binding energy provided as the primary input. The peptides undergo a complex design process, until eventually converging on to an optimal binding affinity, diversified peptide library.

Pepticoms modeling allows further design to overcome problems such as metabolic degradation, solubility and toxicity down the road, together with the addition of probes, cyclization and peptide-mimetic structures.

Our Advantages over Contemporary Methodologies
Contemporary peptide drug design methods are primarily composed of high throughput screening and phage display libraries. While these methods provide experimental binding assays, they have several disadvantages when compared to computational screening:
  • Massive screening assays and phage display libraries are more time consuming and expensive than computational methods.
  • Screening assays and phage display libraries do not provide three dimensional binding models and binding energy component analysis. This may lead to lower diversification of the solution peptides, making them less competent as drug candidates.
  • Computational peptide models are easier to modify, and transform into peptidomimetics and small molecules.

Pepticom undertook upon itself to perform up to three not-for-profit projects per year as part of its values and missions.

Current pro-bono projects
  1. LIVIN with Prof. Dina Ben Yehuda, head of the department of hematology, Hadassah Medical Center. This project focuses on the usage of ab-initio peptide design in the exploration of the cellular role of Livin (ML-IAP), with an emphasis on its role in malignant disease.
  2. Glycogen Branching Enzyme (GBE), with Dr. Or Kahlon, department of neurology, Hadassah Medical Center. This project focuses on the usage of small peptides as possible stabilizing agents in mutated GBE, where the mutation causes a protein misfold. The goal of this project is to see whether stabilizing agents can achieve a medicinal potential.
If you are interested in pro-bono services, please contact us at info@pepticom.com

Please note that this service is available only to academic researchers, for noncommercial purposes.
  • In-Silico
    PEPTIDE DESIGN
  • In-Vitro HIT
    IDENTIFICATION
  • In-Silico/In-Vitro
    LEAD OPTIMIZATION
  • In-Vivo
    VALIDATION
  • PRECLINICAL
    DEVELOPMENT
  • PARTNER/
    COLLABORATOR
  • Innate Immunity PTC-02
  • Cardiovascular PTC-E-02
  •  
  • Alzheimer's Disease
  •  
  • Innate Immunity
  • Innate Immunity
  • Innate Immunity
  • Cancer
  •  
  • Cardiovascular
  •  
  • CNS

Fraunhofer

EMC microcollections

TargetEx

Hebrew University

Tufts Medical Center

Stuttgart University

Our Team
Management
Dr. Immanuel Lerner, C.E.O.
Dr. Lerner has extensive experience in neurobiology, immunology and cancer research using in-vitro and in-vivo models. Immanuel was the key in delivering Pepticom's initial in-vitro proofs of concepts, blocking Toll-like receptor activation in primary mouse macrophages. He holds M.Sc. in biochemistry with distinction and earned a Ph.D. from the Hebrew University of Jerusalem, followed by postdoctoral research in the field of circadian biology.

Dr. Amit Michaeli, C.R.O.
Pepticom's algorithms were developed during Amit's thesis in the Hebrew University of Jerusalem. Amit has extensive algorithm development experience, in both the chemical and financial fields. Amit currently focuses his efforts in Pepticom on the development of new models that define conformational entropy and models of small molecules based on peptide conformations.


Dr. Maayan Elias Robicsek, B.D.O.
Dr. Maayan studied has a BSc. Pharm degree from the Hebrew university and has 12 years of experience in the field. She earned her PhD from the Hebrew university in the medicinal chemistry creating unique databases and prediction models for Cytochrome P450 inhibitors and substrates. Additionally, Maayan holds a master in Business Administration (MBA) specializes in Finance, general and strategic management.

Scientific Advisors
Professor Amiram Goldblum, Director and Founder, Following his earlier studies of Chemistry and Physics and research Quantum Chemistry, Prof. Goldblum is Head of the Molecular Modeling and Drug Design and Discovery Unit at the Institute for Drug Research of the Hebrew University. Prof. Goldblum is a world renowned scientist with more than 100 publications in scientific journals and is a requested speaker in scientific conferences.
 
Dr. Anwar Rayan, Founder
Dr. Anwar Rayan is a research associate at the Hebrew university of Jerusalem and a researcher at the QRC - Qasemi Research Center, Alkasemi College. Dr. Rayan has gained vast experience in the field of drug discovery and algorithms' development while working at the School of Pharmacy at the Hebrew University in Jerusalem and at FMP in Berlin. Dr. Rayan is expert in the field of bioinformatics, chemoinformatics, drug design and drug discovery. He contributed to the development of novel tools for protein/peptide structure prediction, protein-protein docking, drug-likeness, molecular bioactivity indexing. He holds B.Sc. in chemistry with distinction and earned a Ph.D. degree in medicinal chemistry from the Hebrew University of Jerusalem.

Board of Directors
Prof. Amiram Goldblum
Dr. Shmulik Ittah
Dr. Immanuel Lerner
Dr. Amit michaeli
News & Events
  • 8.2013
  • Pepticom undergoes seed investment
  • 9.2013
  • Pepticom initiates multiple projects in the fields of neurology, cancer and cardiovascular diseases.
  • 10.2013
  • Pepticom offices move to a new location: Malha Technology Park (GATI), Building 8, 3rd floor, Jerusalem, Israel.
  • 12.2013
  • New pending patent issued by pepticom in the field of innate immunity.
  • 12.2013
  • EUREKA label approved for pepticom and TargetEx on development of new anti-Alzheimer's disease drugs by designing BACE1 and AChE binding peptides.
  • 1.2014
  • EUREKA label approved for Pepticom in joint collaboration with EMC Microcollections and Stuttgart University (IGVP, Stuttgart), to develop Toll-like receptors modulators.
  • 2.2014
  • Pepticom announces collaboration with Fraunhofer institute to develop innate immunity modulators.
  • 3.2014
  • Pepticom announces a collaboration with Professor Alan S. Kopin at Tufts Medical Center in Boston to develop opioid receptor modulators.
  • 5.2014
  • Invited speakers in BioMed Israel innovation conference.
Contact Us

Pepticom Ltd.
Malha Technology Park (GATI)
Building 8, 3rd floor
Jerusalem, Israel
Email. info@pepticom.com

Immanuel Lerner, Ph.D
CEO
Tel. 972 544 819 947
Email. immanuel.lerner@pepticom.com

Amit Michaeli, Ph.D
MBA CRO
Tel. 972 506 407 061
Email. amit.michaeli@pepticom.com